U.S. stock futures slightly higher after Christmas holiday
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ionis Pharmaceuticals (IONS) PT Raised to $68 at BMO Capital
December 28, 2016 3:55 PM ESTBMO Capital analyst Do Kim reiterated an Outperform rating and rasied his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $61.00) as the firm's Spinraza estimates increase to reflect a faster ramp based on the broad approval and a higher price point... More
Ionis Pharmaceuticals (IONS) Spinraza Approval Expected But a 'Major Positive', Laidlaw Says; PT Up To $65
December 27, 2016 9:31 AM ESTLaidlaw analyst Yale Jen reiterated a Buy rating and raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to of $65.00 (from $59.00) announced the FDA approved Spinraza as a spinal muscular atrophy (SMA) treatment in pediatric and adult (late-onset) patients. IONS earned a... More
Needham & Company Reiterates Buy on Ionis Pharmaceuticals (IONS) Following FDA Approval
December 27, 2016 9:26 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $64 price target on Ionis Pharmaceuticals (NASDAQ: IONS) and partner Biogen were granted FDA approval for SPINRAZA (nusinersen), a treatment for spinal muscular atrophy. SPINRAZA will have a broad label including both children and adults... More
